Recent 8-K filings for OGN

• April 30, 2026, 7:59 PM ET earnings materiality 0.85 negative item 2.02item 9.01 ◈ Earnings Releases

  Organon Q1 revenue $1.46B (-4% YoY); declares $0.02 dividend; Sun Pharma merger pending

  Revenue $1.460B, down 4% as-reported, down 9% ex-FX; Women's Health -16%, Biosimilars +23%.

• April 27, 2026, 7:59 PM ET M&A materiality 1.00 positive item 1.01item 5.02item 7.01item 9.01 ◈ Material Agreements

  Sun Pharma to acquire Organon for $14.00/share in all-cash deal; EV $11.75B

  Acquisition price $14.00/share in cash, a 103% premium to Organon's closing price on April 9, 2026.

• February 20, 2026, 6:59 PM ET other material materiality 0.30 positive item 8.01item 9.01

  Organon Audit Committee completes biosimilar purchase review, finds no improper conduct

  Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.

• February 12, 2026, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon reports FY2025 rev $6.2B (-3%), GAAP EPS $0.72; guides FY2026 rev ~$6.2B, Adj EBITDA ~$1.9B

  Full year 2025 revenue $6.2B, down 3% YoY; GAAP diluted EPS $0.72, adjusted diluted EPS $3.66.

• November 10, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered

  Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).

• November 7, 2025, 6:59 PM ET leadership materiality 0.30 neutral item 5.02

  Organon director Grace Puma will not stand for re-election at 2026 annual meeting

  Grace Puma informed Organon on Nov 3, 2025 she will not seek re-election at the 2026 Annual Meeting.

• October 30, 2025, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 9.01

  Organon sets Executive Chair Carrie S. Cox compensation at $100,000/month

  Carrie S. Cox appointed Executive Chair effective October 26, 2025.

• October 27, 2025, 7:59 PM ET leadership materiality 0.90 negative item 5.02item 8.01item 9.01

  Organon CEO resigns after probe finds improper Nexplanon wholesaler sales; Morrissey named interim CEO

  Kevin Ali resigned as CEO and Board member; no severance or equity retirement benefits.

• August 5, 2025, 7:59 PM ET earnings materiality 0.72 positive item 2.02item 7.01item 9.01

  Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B

  Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.

• June 12, 2025, 7:59 PM ET other material materiality 0.50 neutral item 5.02item 5.07item 9.01

  Organon stockholders approve amended 2021 Incentive Stock Plan adding 7.8M shares

  Amended plan increases share reserve by 7.8M shares; requires 95% of awards to have minimum 1-year vesting.

• May 27, 2025, 7:59 PM ET regulatory materiality 0.65 positive item 8.01item 9.01

  FDA designates Organon's HADLIMA as interchangeable biosimilar to Humira across all presentations

  FDA granted interchangeability for HADLIMA high- and low-concentration (40 mg/0.4 mL, 40 mg/0.8 mL) autoinjectors and high-concentration prefilled syringe.

• May 1, 2025, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 7.01item 8.01item 9.01

  Organon cuts dividend 93% to $0.08/yr; Q1 revenue down 7%, adj EPS $1.02

  Q1 revenue $1.513B, -7% as-reported (-4% ex-FX); GAAP EPS $0.33, non-GAAP adj EPS $1.02.

• April 15, 2025, 7:59 PM ET leadership materiality 0.30 neutral item 5.02item 7.01 ◈ executive_change

  Organon appoints Ramona A. Sequeira to Board of Directors

  Appointment effective July 1, 2025; Board expands to 12 directors.

• February 13, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 7.01item 9.01

  Organon FY2024 revenue $6.4B (+2%); guides FY2025 revenue $6.125-6.325B

  Full year 2024 revenue $6,401M (+2% as-reported, +3% constant currency); diluted EPS $3.33; non-GAAP adjusted diluted EPS $4.11.

• January 21, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Organon CCO Susanne Fiedler departs effective Jan 15, senior advisor until April 30

  Susanne Fiedler ceased performing CCO functions effective January 15, 2025.

• December 23, 2024, 6:59 PM ET other materiality 0.20 neutral item 8.01

  Organon board reduces size to 11 after director McGarry's resignation

  Director Martha E. McGarry resigned from the board; resignation previously announced.

• December 6, 2024, 6:59 PM ET leadership materiality 0.20 neutral item 5.02

  Director Martha E. McGarry resigns from Organon Board effective December 4, 2024

  Martha E. McGarry notified the Board of her resignation effective December 4, 2024.

• November 5, 2024, 6:59 PM ET regulatory materiality 0.60 neutral item 7.01item 9.01

  FDA extends VTAMA sNDA review for atopic dermatitis to March 12, 2025

  FDA extended target action date by 3 months to March 12, 2025; original date was December 12, 2024.

• October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01

  Organon Q3 revenue $1.582B (+4% YoY); narrows FY revenue guidance upward to $6.375-6.425B

  GAAP diluted EPS $1.38; non-GAAP adjusted diluted EPS $0.87 (includes $0.16 IPR&D charge).

• September 23, 2024, 7:59 PM ET M&A materiality 0.75 positive item 1.01item 9.01

  Organon acquires Dermavant Sciences for up to $1.2B; VTAMA drug portfolio

  Total consideration up to $1.2B: $175M upfront, $75M FDA milestone for atopic dermatitis, up to $950M commercial milestones.

• August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 7.01item 9.01

  Organon Q2 2024 revenue flat at $1.607B; Adj. EPS $1.12, down 15% YoY

  Revenue $1.607B flat YoY (up 2% constant currency); net income $195M vs $242M prior year.

• June 6, 2024, 7:59 PM ET other material materiality 0.15 neutral item 5.07

  Organon shareholders elect all four Class III directors, approve say-on-pay and auditor ratification

  All four Class III director nominees elected: Kevin Ali, Martha E. McGarry, Philip Ozuah, Shalini Sharp each received >173M votes for.

• May 17, 2024, 7:59 PM ET debt materiality 0.75 neutral item 1.01item 2.03item 9.01 ◈ Material Agreements ×2

  Organon issues $1B in senior notes, amends credit facilities to extend maturities and reduce rates

  Issued $500M 6.750% senior secured notes due 2034 and $500M 7.875% unsecured notes due 2034.

• May 2, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 7.01item 9.01 ◈ Earnings Releases

  Organon Q1 2024 revenue up 5% to $1.62B; adjusted EPS $1.22, up 13% YoY; 2024 guidance reaffirmed

  Q1 revenue $1,622M (+5% as-reported, +7% constant currency); net income $201M (+14% YoY).

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.69 · Most common event earnings

7 positive 6 negative 11 neutral

source · OGN on sec.gov